explore -WSS

explore

author：leisure time 2025-10-01 14:15:36 - browse：788

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke Thursday at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.

Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.

Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： DeepMind touts AlphaFold's new skills as protein folding AI models face off

WSS

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

All of Us, NIH's precision medicine initiative, gets a big boost

Reframing the conversation around gain

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

'The View' co

Biden White House, tech companies launch new safeguards around emerging AI technology

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Walensky prepares to leave CDC — and Congress — behind

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Walensky prepares to leave CDC — and Congress — behind

Biden White House, tech companies launch new safeguards around emerging AI technology

After affirmative action ruling, medical educators look to 'holistic review'

How to convince healthy people to buy insurance

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicare must police algorithms in Medicare Advantage, Dems say

Hollywood unions extend contract negotiations for actors

Bill would allow buprenorphine prescription for addiction via telehealth

hotspot

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

All of Us, NIH's precision medicine initiative, gets a big boost

Medicare proceeds with plan to claw back hospital funds

A former Republican legislative candidate has been charged for his role in the US Capitol riot

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

A former Republican legislative candidate has been charged for his role in the US Capitol riot

hotspot

knowledge

leisure time

knowledge